• Explore /
  • Poster
  • / Phase II study of conversion therapy using S1/paclitaxel chemotherapy plus apatinib in unresectable gastric cancer (Ahead-G325 trial).

Phase II study of conversion therapy using S1/paclitaxel chemotherapy plus apatinib in unresectable gastric cancer (Ahead-G325 trial).

Abstract Poster

Authors

null

Xiangdong Cheng

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China

Xiangdong Cheng , Zhiyuan Xu , Yian Du , Ping Hu , Guofa Yu , Conggang Hu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Translational Research

Clinical Trial Registration Number

NCT02529878

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 53)

DOI

10.1200/JCO.2017.35.4_suppl.53

Abstract #

53

Poster Bd #

F9

Abstract Disclosures

Similar Posters

First Author: Zhi Peng

First Author: Lin Chen

First Author: Kohei Shitara

First Author: Lin Shen